Related Experiment Videos
Immunodominance: intermolecular competition between MHC class II molecules by covalently linked T cell epitopes
Y Wang1, J A Smith, M L Gefter
1Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Boston, MA 02115.
Journal of Immunology (Baltimore, Md. : 1950)
|May 15, 1992
Summary
Intermolecular competition for MHC class II binding determines immunodominance, challenging prior models. Adjacent sequences alter epitope conformation, impacting T cell recognition and vaccine development.
Area of Science:
- Immunology
- Molecular Biology
- Vaccine Development
Background:
- T cell responses typically focus on a few immunodominant epitopes from complex antigens.
- Mechanisms of immunodominance are thought to involve antigen processing, proteolytic cleavage, and MHC binding affinity.
- T cell receptor (TCR) repertoire limitations can also influence epitope recognition.
Purpose of the Study:
- To investigate if intermolecular competition for MHC class II binding influences immunodominance.
- To analyze factors controlling T cell recognition of covalently linked epitopes.
- To explore the role of adjacent sequences in altering epitope conformation and T cell recognition.
Main Methods:
- Covalent linkage of T cell epitopes.
- Analysis of T cell recognition of linked epitopes.
- Assessment of major histocompatibility complex (MHC) class II binding affinities.
Main Results:
- Immunodominance can be determined by intermolecular competition for MHC class II binding between linked epitopes.
- T cell recognition of the dominant epitope was not affected by antigen processing or solely by MHC binding affinity.
- Adjacent sequences were shown to subtly alter epitope conformation, significantly changing T cell recognition.
Conclusions:
- Intermolecular competition is a key mechanism determining immunodominance.
- Epitope conformation, influenced by adjacent sequences, plays a critical role in T cell recognition.
- Findings have implications for understanding immune responses and designing synthetic peptide vaccines.